Loading company…
Paltech develops precision medicine approaches for managing and treating type 2 diabetes.
Based in Paris, France, Paltech applies molecular analysis to identify targets and patient-specific patterns for type 2 diabetes treatments. Its approach aims to optimise how medication interacts with organs. Founded in 2020 by Réginald Allouche and Charles-Henri Malbert, the company raised EUR 1 million in venture funding in July 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in